PROAIR™ HFA (ALBUTEROL SULFATE)
INHALATION AEROSOL
For Oral Inhalation Only

PRESCRIBING INFORMATION

DESCRIPTION

The active ingredient of PROAIR HFA (albuterol sulfate) Inhalation Aerosol is
albuterol sulfate, a racemic salt, of albuterol. Albuterol sulfate is a relatively
selective beta₂-adrenergic agonist (see CLINICAL PHARMACOLOGY).
Albuterol sulfate has the chemical name α₁-[(tert-butylamino) methyl]-4-
hydroxy-m-xylene-α,α'-diol sulfate (2:1) (salt), and has the following chemical
structure:

![Chemical Structure of Albuterol Sulfate](image)

The molecular weight of albuterol sulfate is 576.7, and the empirical formula is
(C₁₃H₂₁NO₅)₂•H₂SO₄. Albuterol sulfate is a white to off-white crystalline
powder. It is soluble in water and slightly soluble in ethanol. Albuterol sulfate is
the official generic name in the United States, and salbutamol sulfate is the World
Health Organization recommended generic name. PROAIR HFA Inhalation
Aerosol is a pressurized metered-dose aerosol unit for oral inhalation. It contains
a microcrystalline suspension of albuterol sulfate in propellant HFA-134a (1,1,1,
2-tetrafluoroethane) and ethanol.

Prime the inhaler before using for the first time and in cases where the inhaler has
not been used for more than 2 weeks by releasing three “test sprays” into the air,
away from the face. After priming, each actuation delivers 108 mcg albuterol
sulfate, from the actuator mouthpiece (equivalent to 90 mcg of albuterol base).
Each canister provides 200 actuations (inhalations).

This product does not contain chlorofluorocarbons (CFCs) as the propellant.

CLINICAL PHARMACOLOGY

Mechanism of Action

Activation of beta₂-adrenergic receptors on airway smooth muscle leads to the
activation of adenylcyclase and to an increase in the intracellular concentration of
cyclic-3', 5'-adenosine monophosphate (cyclic AMP). This increase of cyclic
AMP is associated with the activation of protein kinase A, which in turn inhibits
the phosphorylation of myosin and lowers intracellular ionic calcium
concentrations, resulting in muscle relaxation. Albuterol relaxes the smooth
muscle of all airways, from the trachea to the terminal bronchioles. Increased
cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. While it is recognized that beta2-adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there are beta-receptors in the human heart, 10% to 50% of which are cardiac beta2-adrenergic receptors. The precise function of these receptors has not been established (See WARNINGS: Cardiovascular Effects).

However, all beta-adrenergic agonist drugs can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Preclinical

Intravenous studies in rats with albuterol sulfate have demonstrated that albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), albuterol concentrations were found to be 100 times those in the whole brain.

Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when β-agonists and methylxanthines were administered concurrently. The clinical significance of these findings is unknown.

Propellant HFA-134a is devoid of pharmacological activity except at very high doses in animals (380 - 1300 times the maximum human exposure based on comparisons of AUC values), primarily producing ataxia, tremors, dyspnea, or salivation. These are similar to effects produced by the structurally related chlorofluorocarbons (CFCs), which have been used extensively in metered-dose inhalers.

In animals and humans, propellant HFA-134a was found to be rapidly absorbed and rapidly eliminated, with an elimination half-life of 3 - 27 minutes in animals and 5 - 7 minutes in humans. Time to maximum plasma concentration (T_{max}) and mean residence time are both extremely short leading to a transient appearance of HFA-134a in the blood with no evidence of accumulation.

Pharmacokinetics

The systemic levels of albuterol are low after inhalation of recommended doses. In a crossover study conducted in healthy male and female volunteers, high cumulative doses of PROAIR HFA Inhalation Aerosol (1,080 mcg of albuterol base administered over one hour) yielded mean peak plasma concentrations (C_{max}) and systemic exposure (AUC_{inf}) of approximately 4,100 pg/mL and 28,426 pg•hr/mL, respectively compared to approximately 3,900 pg/mL and 28,395 pg•hr/mL, respectively following the same dose of an active HFA-134a albuterol
inhaler comparator. The terminal plasma half-life of albuterol delivered by
PROAIR HFA Inhalation Aerosol was approximately 6 hours. Comparison of the
pharmacokinetic parameters demonstrated no differences between the products.

No pharmacokinetic studies for PROAIR HFA Inhalation Aerosol have been
conducted in neonates, children, or elderly subjects.

**Metabolism and Elimination**

Information available in the published literature suggests that the primary enzyme
responsible for the metabolism of albuterol in humans is SULTIA3
(sulfotransferase). When racemic albuterol was administered either intravenously
or via inhalation after oral charcoal administration, there was a 3- to 4-fold
difference in the area under the concentration-time curves between the (R)- and
(S)-albuterol enantiomers, with (S)-albuterol concentrations being consistently
higher. However, without charcoal pretreatment, after either oral or inhalation
administration the differences were 8- to 24-fold, suggesting that the (R)-albuterol
is preferentially metabolized in the gastrointestinal tract, presumably by
SULTIA3.

The primary route of elimination of albuterol is through renal excretion (80% to
100%) of either the parent compound or the primary metabolite. Less than 20%
of the drug is detected in the feces. Following intravenous administration of
racemic albuterol, between 25% and 46% of the (R)-albuterol fraction of the dose
was excreted as unchanged (R)-albuterol in the urine.

**Special Populations**

**Hepatic Impairment:** The effect of hepatic impairment on the pharmacokinetics
of PROAIR HFA Inhalation Aerosol has not been evaluated.

**Renal Impairment:** The effect of renal impairment on the pharmacokinetics of
albuterol was evaluated in 5 subjects with creatinine clearance of 7 to 53 mL/min,
and the results were compared with those from healthy volunteers. Renal disease
had no effect on the half-life, but there was a 67% decline in albuterol clearance.
Caution should be used when administering high doses of PROAIR HFA
Inhalation Aerosol to patients with renal impairment.

**Clinical Trials**

In a 6-week, randomized, double-blind, placebo-controlled trial, PROAIR HFA
Inhalation Aerosol (58 patients) was compared to a matched placebo HFA
Inhalation Aerosol (58 patients) in asthmatic patients 12 to 76 years of age at a
dose of 180 mcg albuterol four times daily. An evaluator-blind marketed active
comparator HFA-134a albuterol inhaler arm (56 patients) was included.

Serial FEV\(_1\) measurements, shown below as percent change from test-day
baseline at Day 1 and at Day 43, demonstrated that two inhalations of PROAIR
HFA Inhalation Aerosol produced significantly greater improvement in FEV$_1$ over the pre-treatment value than the matched placebo, as well as a comparable bronchodilator effect to the marketed active comparator HFA-134a albuterol inhaler.
FEV₁ as Mean Percent Change from Test-Day Pre-Dose in a 6-Week Clinical Trial

Day 1

Day 43
In this study, 31 of 58 patients treated with PROAIR HFA Inhalation Aerosol achieved a 15% increase in FEV$_1$ within 30 minutes post-dose on Day 1. In these patients, the median time to onset, median time to peak effect, and median duration of effect were 8.2 minutes, 47 minutes, and approximately 3 hours, respectively. In some patients, the duration of effect was as long as 6 hours.

In a placebo-controlled, single-dose, crossover study in which PROAIR HFA Inhalation Aerosol, administered at albuterol doses of 90, 180 and 270 mcg, produced bronchodilator responses significantly greater than those observed with a matched placebo HFA Inhalation Aerosol and comparable to a marketed active comparator HFA-134a albuterol inhaler.

In a randomized, single-dose, crossover study in 24 adults and adolescents with exercise-induced bronchospasm (EIB), two inhalations of PROAIR HFA taken 30 minutes before exercise prevented EIB for the hour following exercise (defined as maintenance of FEV$_1$ within 80% of post-dose, pre-exercise baseline values) in 83% (20 of 24) of patients as compared to 25% (6 of 24) of patients when they received placebo.

Some patients who participated in these clinical trials were using concomitant steroid therapy.

**INDICATIONS AND USAGE**

PROAIR HFA Inhalation Aerosol is indicated in adults and children 12 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

**CONTRAINDICATIONS**

PROAIR HFA Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to albuterol and any other PROAIR HFA Inhalation Aerosol components.

**WARNINGS**

Paradoxical Bronchospasm: PROAIR HFA Inhalation Aerosol can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs, PROAIR HFA Inhalation Aerosol should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of PROAIR HFA Inhalation Aerosol than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

Use of Anti-inflammatory Agents: The use of beta-adrenergic-agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids, to the therapeutic regimen.

Cardiovascular Effects: PROAIR HFA Inhalation Aerosol, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of PROAIR HFA Inhalation Aerosol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, PROAIR HFA Inhalation Aerosol, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.

Immediate Hypersensitivity Reactions: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. The potential for hypersensitivity must be considered in the clinical evaluation of patients who experience immediate hypersensitivity reactions while receiving PROAIR HFA Inhalation Aerosol.

PRECAUTIONS

General

PROAIR HFA Inhalation Aerosol, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive
disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.

Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, PROAIR HFA Inhalation Aerosol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.

Information for Patients

See illustrated Patient’s Instructions for Use. Shake well before use. Patients should be given the following information:

Prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks by releasing three “test sprays” into the air, away from the face.

Keeping the plastic actuator mouthpiece clean is very important to prevent medication build-up and blockage. Wash the mouthpiece, shake to remove excess water, and air dry thoroughly at least once a week. The inhaler may cease to deliver medication if not properly cleaned.

Clean the mouthpiece (with the canister removed) by running warm water through the top and bottom of the mouthpiece for 30 seconds at least once a week. Shake to remove excess water, then air-dry thoroughly (such as overnight). Blockage from medication build-up or improper medication delivery may result from failure to thoroughly air dry the mouthpiece.

If the mouthpiece should become blocked (little or no medication coming out of the mouthpiece), the blockage may be removed by washing as described above.

If it is necessary to use the inhaler before it is completely dry, shake off excess water, replace canister, test spray twice away from face, and take the prescribed dose. After such use, the mouthpiece should be rewashed and allowed to air dry thoroughly.

The action of PROAIR HFA Inhalation Aerosol should last for 4 to 6 hours. Do not use PROAIR HFA Inhalation Aerosol more frequently than recommended. Do not increase the dose or frequency of doses of PROAIR HFA Inhalation Aerosol without consulting your physician. If you find that treatment with PROAIR HFA Inhalation Aerosol becomes less effective for symptomatic relief,
your symptoms become worse, and/or you need to use the product more frequently than usual, seek medical attention immediately. While you are taking PROAIR HFA Inhalation Aerosol, other inhaled drugs and asthma medications should be taken only as directed by your physician. If you are pregnant or nursing, contact your physician about the use of PROAIR HFA Inhalation Aerosol.

Common adverse effects of treatment with inhaled albuterol include palpitations, chest pain, rapid heart rate, tremor, or nervousness. Effective and safe use of PROAIR HFA Inhalation Aerosol includes an understanding of the way that it should be administered.

Use PROAIR HFA Inhalation Aerosol only with the actuator supplied with the product. Discard the canister after 200 sprays have been used. Never immerse the canister in water to determine how full the canister is (“float test”).

Drug Interactions

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with PROAIR HFA Inhalation Aerosol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as PROAIR HFA Inhalation Aerosol, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic-blocking agents in patients with asthma. In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution.

Diuretics: The ECG changes and/or hypokalemia which may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics.

Digoxin: Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease
who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and PROAIR HFA Inhalation Aerosol.

**Monoamine Oxidase Inhibitors or Tricyclic Antidepressants:** PROAIR HFA Inhalation Aerosol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the cardiovascular system may be potentiated.

**Carcinogenesis, Mutagenesis and Impairment of Fertility**

In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a dose-related increase in the incidence of benign leiomyomas of the mesovarium at and above dietary doses of 2 mg/kg (approximately 15 times the maximum recommended daily inhalation dose for adults on a mg/m² basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. In an 18-month study in CD-1 mice, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 1,600 times the maximum recommended daily inhalation dose for adults on a mg/m² basis). In a 22-month study in Golden Hamsters, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg (approximately 210 times the maximum recommended daily inhalation dose for adults on a mg/m² basis).

Albuterol sulfate was not mutagenic in the Ames test or a mutation test in yeast. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay.

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 310 times the maximum recommended daily inhalation dose for adults on a mg/m² basis).

**Pregnancy: Teratogenic Effects: Pregnancy Category C**

Albuterol sulfate has been shown to be teratogenic in mice. A study in CD-1 mice given albuterol sulfate subcutaneously showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg (less than the maximum recommended daily inhalation dose for adults on a mg/m² basis) and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg (approximately 8 times the maximum recommended daily inhalation dose for adults on a mg/m² basis). The drug did not induce cleft palate formation at the low dose 0.025 mg/kg (less than the maximum recommended daily inhalation dose for adults on a mg/m² basis). Cleft palate also occurred in 22 of
72 (30.5%) fetuses treated subcutaneously with 2.5 mg/kg isoproterenol (positive control).

A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol sulfate was administered orally at 50 mg/kg (approximately 630 times the maximum recommended daily inhalation dose for adults on a mg/m$^2$ basis).

In an inhalation reproduction study in Sprague-Dawley rats, the albuterol sulfate/HFA-134a formulation did not exhibit any teratogenic effects at 10.5 mg/kg (approximately 65 times the maximum recommended daily inhalation dose for adults on a mg/m$^2$ basis).

A study in which pregnant rats were dosed with radiolabeled albuterol sulfate demonstrated that drug-related material is transferred from the maternal circulation to the fetus.

There are no adequate and well-controlled studies of albuterol sulfate in pregnant women. PROAIR HFA Inhalation Aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. Some of the mothers were taking multiple medications during their pregnancies. Because no consistent pattern of defects can be discerned, a relationship between albuterol use and congenital anomalies has not been established.

**Use in Labor and Delivery**

Because of the potential for beta-agonist interference with uterine contractility, use of PROAIR HFA Inhalation Aerosol for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

**Tocolysis:**

PROAIR HFA Inhalation Aerosol has not been approved for the management of pre-term labor. The benefit:risk ratio when albuterol is administered for tocolysis has not been established. Serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta2-agonists, including albuterol.

**Nursing Mothers**
Plasma levels of albuterol sulfate and HFA-134a after inhaled therapeutic doses are very low in humans, but it is not known whether the components of PROAIR HFA Inhalation Aerosol are excreted in human milk.

Caution should be exercised when PROAIR HFA Inhalation Aerosol is administered to a nursing woman. Because of the potential for tumorigenicity shown for albuterol in animal studies and lack of experience with the use of PROAIR HFA Inhalation Aerosol by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatrics**

The safety and effectiveness of PROAIR HFA Inhalation Aerosol in pediatric patients below the age of 12 years have not been established.

**Geriatrics**

Clinical studies of PROAIR HFA Inhalation Aerosol did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Albuterol is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

**ADVERSE REACTIONS**

A total of 973 subjects were treated with PROAIR HFA Inhalation Aerosol during the worldwide clinical development program.

The adverse reaction information presented in the table below concerning PROAIR HFA Inhalation Aerosol is derived from a 6-week, blinded study which compared PROAIR HFA Inhalation Aerosol (180 mcg four times daily) with a double-blinded matched placebo HFA-Inhalation Aerosol and an evaluator-blinded marketed active comparator HFA-134a albuterol inhaler in 172 asthmatic patients 12 to 76 years of age. The table lists the incidence of all adverse events (whether considered by the investigator drug related or unrelated to drug) from this study which occurred at a rate of 3% or greater in the PROAIR HFA...
Inhalation Aerosol treatment group and more frequently in the PROAIR HFA Inhalation Aerosol treatment group than in the matched placebo group. Overall, the incidence and nature of the adverse events reported for PROAIR HFA Inhalation Aerosol and the marketed active comparator HFA-134a albuterol inhaler were comparable.
<table>
<thead>
<tr>
<th>Body System/Adverse Event (as Preferred Term)</th>
<th>PROAIR HFA Inhalation Aerosol (N = 58)</th>
<th>Matched Placebo HFA-134a Inhalation Aerosol (N = 58)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a Whole Headache</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Cardiovascular Tachycardia</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Nervous System Dizziness</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory System Pharyngitis</td>
<td>14</td>
<td>7</td>
</tr>
<tr>
<td>System</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

* This table includes all adverse events (whether considered by the investigator drug related or unrelated to drug) which occurred at an incidence rate of at least 3.0% in the PROAIR HFA Inhalation Aerosol group and more frequently in the PROAIR HFA Inhalation Aerosol group than in the placebo HFA Inhalation Aerosol group.

Adverse events reported by less than 3% of the patients receiving PROAIR HFA Inhalation Aerosol but by a greater proportion of PROAIR HFA Inhalation Aerosol patients than the matched placebo patients, which have the potential to be related to PROAIR HFA Inhalation Aerosol, included chest pain, infection, diarrhea, glossitis, accidental injury (nervous system), anxiety, dyspnea, ear disorder, ear pain, and urinary tract infection.

In small cumulative dose studies, tremor, nervousness, and headache were the most frequently occurring adverse events.

**Postmarketing**

In addition to the adverse events reported in the clinical trials, the following adverse events have been observed in postapproval use of inhaled albuterol. These events have been chosen for inclusion due to their seriousness, their frequency of reporting, or their likely beta-mediated mechanism: urticaria, angioedema, rash, bronchospasm, hoarseness, oropharyngeal edema, and arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles). Because these events have been reported spontaneously from a population of unknown size, estimates of frequency cannot be made. In addition, albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vertigo, central nervous system stimulation, insomnia, headache, and drying or irritation of the oropharynx.

Post-marketing safety data with PROAIR HFA Inhalation Aerosol are generally consistent with both adverse events in the clinical trials and in the use of inhaled
albuterol. Reports have included rare cases of aggravated bronchospasm, lack of
efficacy, asthma exacerbation (reported fatal in one case), muscle cramps, and
various oropharyngeal side-effects such as throat irritation, altered taste, glossitis,
tongue ulceration, and gagging.

OVERDOSAGE

The expected symptoms with overdosage are those of excessive beta-adrenergic
stimulation and/or occurrence or exaggeration of any of the symptoms listed
under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or
hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias,
nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue,
malaise, and insomnia.

Hypokalemia may also occur. As with all sympathomimetic medications, cardiac
arrest and even death may be associated with abuse of PROAIR HFA Inhalation
Aerosol.

Treatment consists of discontinuation of PROAIR HFA Inhalation Aerosol
together with appropriate symptomatic therapy. The judicious use of a
cardioselective beta-receptor blocker may be considered, bearing in mind that
such medication can produce bronchospasm. There is insufficient evidence to
determine if dialysis is beneficial for overdosage of PROAIR HFA Inhalation
Aerosol.

The oral median lethal dose of albuterol sulfate in mice is greater than
2,000 mg/kg (approximately 6,300 times the maximum recommended daily
inhalation dose for adults on a mg/m$^2$ basis). In mature rats, the subcutaneous
median lethal dose of albuterol sulfate is approximately 450 mg/kg
(approximately 2,800 times the maximum recommended daily inhalation dose for
adults on a mg/m$^2$ basis). In young rats, the subcutaneous median lethal dose is
approximately 2,000 mg/kg (approximately 13,000 times the maximum
recommended daily inhalation dose for adults on a mg/m$^2$ basis). The inhalation
median lethal dose has not been determined in animals.

DOSAGE AND ADMINISTRATION

For treatment of acute episodes of bronchospasm or prevention of asthmatic
symptoms, the usual dosage of PROAIR HFA Inhalation Aerosol for adults and
children 12 years and older is two inhalations repeated every 4 to 6 hours. More
frequent administration or a larger number of inhalations is not recommended. In
some patients, one inhalation every 4 hours may be sufficient.
It is recommended to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than two weeks by releasing three “test sprays” into the air, away from the face.

Exercise-Induced Bronchospasm Prevention: The usual dosage for adults and children 12 years of age or older is two inhalations 15 to 30 minutes before exercise.

If a previously effective dosage regimen fails to provide the usual response, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

Cleaning: To maintain proper use of this product and to prevent medication build-up and blockage, it is important to keep the plastic mouthpiece clean. Wash the mouthpiece and air dry thoroughly at least once a week. If the mouthpiece becomes blocked, washing the mouthpiece will remove the blockage. The inhaler may cease to deliver medication if not properly cleaned and air dried. See-

Information For Patients.

HOW SUPPLIED

PROAIR HFA (albuterol sulfate) Inhalation Aerosol is supplied as a pressurized aluminum canister with a red plastic actuator and white dust cap each in boxes of one. Each canister contains 8.5 g of the formulation and provides 200 actuations (NDC 59310-179-20). Each actuation delivers 120 mcg of albuterol sulfate from the canister valve and 108 mcg of albuterol sulfate from the actuator mouthpiece (equivalent to 90 mcg of albuterol base).

Rx only.

SHAKE WELL BEFORE USE. Store between 15° and 25°C (59° and 77°F). Contents under pressure. Do not puncture or incinerate. Protect from freezing temperatures and prolonged exposure to direct sunlight. Exposure to temperatures above 120°F may cause bursting. For best results, canister should be at room temperature before use. Avoid spraying in eyes. Keep out of reach of children.

The red actuator supplied with PROAIR HFA Inhalation Aerosol should not be used with the canister from any other inhalation aerosol products. The PROAIR HFA Inhalation Aerosol canister should not be used with the actuator from any other inhalation aerosol products.

The labeled amount of medication in each actuation cannot be assured after 200 actuations, even though the canister may not be completely empty.
Discard the inhaler (canister plus actuator) after 200 actuations have been used. Never immerse the canister into water to determine how full the canister is (“float test”).

PROAIR HFA Inhalation Aerosol does not contain chlorofluorocarbons (CFCs) as the propellant.

Manufactured by:
IVAX Pharmaceuticals Ireland
Waterford, Ireland
For
IVAX Laboratories, Inc.
Miami, FL 33137 USA

Copyright ©2006, IVAX Laboratories, Inc.
All rights reserved.

PROAIR™ is a trademark of IVAX Laboratories, Inc.